Pharmacological management of agitation among individuals with moderate to severe acquired brain injury: A systematic review

References

• Chang VC, Guerriero EN, Colantonio A. Epidemiology of work‐related traumatic brain injury: A systematic review. Am J Ind Med. 2015;58(4):353–77.
   PubMed Web of Science ®Google Scholar
• Bhatnagar S, Laccarino MA, Zafonte R. Pharmacotherapy in rehabilitation of post-acute traumatic brain injury. Brain Res. 2016;1640:164–79.
   PubMed Web of Science ®Google Scholar
• Stéfan A, Mathé J-F. What are the disruptive symptoms of behavioral disorders after traumatic brain injury? A systematic review leading to recommendations for good practices. Ann Phys Rehabil Med. 2016;59:5–17.
   PubMed Web of Science ®Google Scholar
• Luaute J, Plantier D, Wiart L, Tell L. Care management of the agitation or aggressiveness crisis in patients with TBI. Systematic review of the literature and practice recommendations. Ann Phys Rehabil Med. 2016;59(1):58–67.
   PubMed Web of Science ®Google Scholar
• Rosati DL. Early polyneuropharmacologic intervention in brain injury agitation. Am J Phys Med Rehabil. 2002;81(2):90–93.
   PubMed Web of Science ®Google Scholar
• Hammond FM, Sherer M, Malec JF, Zafonte RD, Whitney M, Bell K, Dikmen S, Bogner J, Mysiw J, Pershad R. Amantadine effect on perceptions of irritability after traumatic brain injury: results of the amantadine irritability multisite study. J Neurotrauma. 2015;32(16):1230–38.
   PubMed Web of Science ®Google Scholar
• Hammond FM, Bickett AK, Norton JH, Pershad R. Effectiveness of amantadine hydrochloride in the reduction of chronic traumatic brain injury irritability and aggression. J Head Trauma Rehabil. 2014;29(5):391–99.
   PubMed Web of Science ®Google Scholar
• Eisenberg ME, Im B, Swift P, Flanagan SR. Management of traumatic brain injury-related agitation. Crit Reviews™ Phys Rehabil Med. 2009;21:3–4.
   Google Scholar
• Bayley M, Teasell R, Marshall S, Cullen N, Colantonio A, Kua A. ABIKUS evidence based recommendations for rehabilitation of moderate to severe acquired brain injury; Toronto, Ontario, Canada: Ontario Neurotrauma Foundation; 2007.
   Google Scholar
• Scottish Intercollegiate Guidelines Network (SIGN). Brain injury rehabilitation in adults: SIGN; 2013. Available from http://www.sign.ac.uk
   Google Scholar
• Corrigan JD, Mysiw WJ. Agitation following traumatic head injury: equivocal evidence for a discrete stage of cognitive recovery. Arch Phys Med Rehabil. 1988;69(7):487–92.
   PubMed Web of Science ®Google Scholar
• Levy M, Berson A, Cook T, Bollegala N, Seto E, Tursanski S, Kim J, Sockalingam S, Rajput A, Krishnadev N, et al. Treatment of agitation following traumatic brain injury: A review of the literature. Neuro Rehabil. 2005;20:279–306.
   Google Scholar
• Maher CG, Sherrington C, Herbert RD, Moseley AM, Elkins M. Reliability of the PEDro scale for rating quality of randomized controlled trials. Phys Ther. 2003;83(8):713–21.
   PubMed Web of Science ®Google Scholar
• Straus SE, Richardson WS, Glasziou P, Haynes RB. Evidencebased medicine: How to practice and teach EBM. 3rd ed. Toronto: Elsevier Churchill Livingstone; 2005.
   Google Scholar
• Brooke MM, Patterson DR, Questad KA, Cardenas D, Farrel-Roberts L. The treatment of agitation during initial hospitalization after traumatic brain injury. Arch Phys Med Rehabil. 1992;73(10):917–21.
   PubMed Web of Science ®Google Scholar
• Greendyke RM, Kanter DR. Therapeutic effects of pindolol on behavioral disturbances associated with organic brain disease: a double blind study. J Clin Psychiatry. 1986;47:423–26.
   PubMed Web of Science ®Google Scholar
• Meythaler JM, Depalma L, Devivo MJ, Guin-Renfroe S, Novack TA. Sertraline to improve arousal and alertness in severe traumatic brain injury secondary to motor vehicle crashes. Brain Inj. 2001;15(4):321–31.
   PubMed Web of Science ®Google Scholar
• Schneider WN, Drew-Cates J, Wong TM, Dombovy ML. Cognitive and behavioural efficacy of amantadine in acute traumatic brain injury: an initial double-blind placebo-controlled study. Brain Inj. 1999;13(11):863–72.
   PubMed Web of Science ®Google Scholar
• Rao N, Jellinek HM, Woolston DC. Agitation in closed head injury: haloperidol effects on rehabilitation outcome. Arch Phys Med Rehabil. 1985;66(1):30–34.
   PubMed Web of Science ®Google Scholar
• Chatham Showalter PE, Netsky Kimmel D. Agitated symptom response to divalproex following acute brain injury. J Neuropsychiatry Clin Neurosci. 2000;12(3):395–97.
   PubMed Web of Science ®Google Scholar
• Maryniak O, Manchanda R, Velani A. Methotrimeprazine in the treatment of agitation in acquired brain injury patients. Brain Inj. 2001;15(2):167–74.
   PubMed Web of Science ®Google Scholar
• Nickels JL, Schneider WN, Dombovy ML, Wong TM. Clinical use of amantadine in brain injury rehabilitation. Brain Inj. 1994;8(8):709–18.
   PubMed Web of Science ®Google Scholar
• Wroblewski BA, Joseph AB, Kupfer J, Kalliel K. Effectiveness of valproic acid on destructive and aggressive behaviours in patients with acquired brain injury. Brain Inj. 1997;11(1):37–47.
   PubMed Web of Science ®Google Scholar
• Chahine LM, Chemali Z. Du rire aux larmes: pathological laughing and crying in patients with traumatic brain injury and treatment with lamotrigine. Epilepsy & Behavior: E&B 2006;8(3):610–15.
   PubMed Web of Science ®Google Scholar
• Azouvi P, Jokic C, Attal N, Denys P, Markabi S, Bussel B. Carbamazepine in agitation and aggressive behaviour following severe closed-head injury: results of an open trial. Brain Inj. 1999;13(10):797–804.
   PubMed Web of Science ®Google Scholar
• Glenn MB, Wroblewski B, Parziale J, Levine L, Whyte J, Rosenthal M. Lithium carbonate for aggressive behavior or affective instability in ten brain-injured patients. Am J Phys Med Rehabil. 1989;68(5):221–26.
   PubMed Web of Science ®Google Scholar
• Kant R, Smith-Seemiller L, Zeiler D. Treatment of aggression and irritability after head injury. Brain Inj. 1998;12(8):661–66.
   PubMed Web of Science ®Google Scholar
• Kim E, Bijlani M. A Pilot Study of Quetiapine Treatment of Aggression Due to Traumatic Brain Injury. J Neuropsychiatry Clin Neurosci. 2006;18(4):547–49.
   PubMed Web of Science ®Google Scholar
• Mysiw WJ, Jackson RD, Corrigan JD. Amitriptyline for post-traumatic agitation. Am J Phys Med Rehabil. 1988;67(1):29–33.
   PubMed Web of Science ®Google Scholar
• Noé E, Ferri J, Trénor C, Chirivella J. Efficacy of ziprasidone in controlling agitation during post-traumatic amnesia. Behav Neurol. 2007;18(1):7–11.
   PubMed Web of Science ®Google Scholar
• Stanislav SW, Childs A. Evaluating the usage of droperidol in acutely agitated persons with brain injury. Brain Inj. 2000;14(3):261–65.
   PubMed Web of Science ®Google Scholar
• Rosell DR, Siever LJ. The neurobiology of aggression and violence. CNS Spectr 2015;20(3):254–79.
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Kotsaftis A. Use of sodium valproate in violent and aggressive behaviors: a critical review. J Clin Psychiatry. 2000;61(2):123–28.
   PubMed Web of Science ®Google Scholar
• Morrison TR, Melloni RH Jr. The role of serotonin, vasopressin, and serotonin/vasopressin interactions in aggressive behavior. Curr Top Behav Neurosci. 2014;17:189–228.
   PubMedGoogle Scholar
• Nakajima S, Gerretsen P, Takeuchi H, Caravaggio F, Chow T, Le Foll B, Mulsant B, Pollock B, Graff-Guerrero A. The potential role of dopamine D(3) receptor neurotransmission in cognition. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2013;23(8):799–813.
   PubMed Web of Science ®Google Scholar
• Ranen NG, Lipsey JR, Treisman G, Ross CA. Sertraline in the treatment of severe aggressiveness in Huntington’s disease. J Neuropsychiatry Clin Neurosci. 1996;8(3):338–40.
   PubMed Web of Science ®Google Scholar
• Luiselli JK, Blew P, Keane J, Thibadeau S, Holzman T. Pharmacotherapy for severe aggression in a child with autism: “open label” evaluation of multiple medications on response frequency and intensity of behavioral intervention. J Behav Ther Exp Psychiatry. 2000;31(3–4):219–30.
   PubMed Web of Science ®Google Scholar
• McDougle CJ, Brodkin ES, Naylor ST, Carlson DC, Cohen DJ, Price LH. Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation. J Clin Psychopharmacol. 1998;18(1):62–66.
   PubMed Web of Science ®Google Scholar
• Hellings JA, Kelley LA, Gabrielli WF, Kilgore E, Shah P. Sertraline response in adults with mental retardation and autistic disorder. J Clin Psychiatry. 1996;57(8):333–36.
   PubMed Web of Science ®Google Scholar
• Kavoussi RJ, Liu J, Coccaro EF. An open trial of sertraline in personality disordered patients with impulsive aggression. J Clin Psychiatry. 1994;55(4):137–41.
   PubMed Web of Science ®Google Scholar
• Hubsher G, Haider M, Okun MS. Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology. 2012;78(14):1096–99.
   PubMed Web of Science ®Google Scholar
• Kraus MF, Smith GS, Butters M, Donnell AJ, Dixon E, Yilong C, Marion D. Effects of the dopaminergic agent and NMDA receptor antagonist amantadine on cognitive function, cerebral glucose metabolism and D2 receptor availability in chronic traumatic brain injury: a study using positron emission tomography (PET). Brain Inj. 2005;19(7):471–79.
   PubMed Web of Science ®Google Scholar
• Sawyer E, Mauro LS, Ohlinger MJ. Amantadine enhancement of arousal and cognition after traumatic brain injury. Ann Pharmacother. 2008;42(2):247–52.
   PubMed Web of Science ®Google Scholar
• Kraus MF, Maki PM. Effect of amantadine hydrochloride on symptoms of frontal lobe dysfunction in brain injury: case studies and review. J Neuropsychiatry Clin Neurosci 1997;9(2):222–30.
   PubMed Web of Science ®Google Scholar
• Amato D. Serotonin in antipsychotic drugs action. Behav Brain Res. 2015;277:125–35.
   PubMed Web of Science ®Google Scholar
• Linton D, Barr AM, Honer WG, Procyshyn RM. Antipsychotic and psychostimulant drug combination therapy in attention deficit/hyperactivity and disruptive behavior disorders: a systematic review of efficacy and tolerability. Curr Psychiatry Rep. 2013;15(5):355.
   PubMed Web of Science ®Google Scholar
• Victoroff J, Coburn K, Reeve A, Sampson S, Shillcutt S. Pharmacological management of persistent hostility and aggression in persons with schizophrenia spectrum disorders: a systematic review. J Neuropsychiatry Clin Neurosci. 2014;26(4):283–312.
   PubMed Web of Science ®Google Scholar
• Young SL, Taylor M, Lawrie SM. First do no harm. A Systematic Review of the Prevalence and Management of Antipsychotic Adverse Effects. Journal of Psychopharmacology (Oxford, England). 2015;29(4):353–62.
   Google Scholar
• Volavka J. Can aggressive behavior in humans be modified by beta blockers?. Postgrad Med. 1988;Spec No:163–168. Available from https://www.ncbi.nlm.nih.gov/pubmed/2894657
   PubMed Web of Science ®Google Scholar
• Brantigan CO, Brantigan TA, Joseph N. Effect of beta blockade and beta stimulation on stage fright. Am J Med. 1982;72(1):88–94.
   PubMed Web of Science ®Google Scholar
• Elliott FA. Propranolol for the control of belligerent behavior following acute brain damage. Ann Neurol. 1977;1(5):489–91.
   PubMed Web of Science ®Google Scholar
• Jenkins SC, Maruta T. Therapeutic use of propranolol for intermittent explosive disorder. Mayo Clinic Proceedings. 1987;62(3):204–14.
   PubMed Web of Science ®Google Scholar
• Mattes JA. Metoprolol for intermittent explosive disorder. Am J Psychiatry. 1985;142(9):1108–09.
   PubMed Web of Science ®Google Scholar
• Luchins DJ, Dojka D. Lithium and propranolol in aggression and self-injurious behavior in the mentally retarded. Psychopharmacol Bull. 1989;25(3):372–75.
   PubMedGoogle Scholar
• Rajkumar RP. Successful management of difficult-to-treat aggression with low-dose propranolol in a patient with intellectual disability: a case report. Primary Care Companion for CNS Disorders. 2012;14:5.
   Google Scholar
• Ratey JJ, Morrill R, Oxenkrug G. Use of propranolol for provoked and unprovoked episodes of rage. Am J Psychiatry. 1983;140(10):1356–57.
   PubMed Web of Science ®Google Scholar
• Ruedrich SL, Grush L, Wilson J. Beta adrenergic blocking medications for aggressive or self-injurious mentally retarded persons. Ajmr. 1990;95(1):110–19.
   Google Scholar
• Peskind ER, Tsuang DW, Bonner LT, Pascualy M, Riekse RG, Snowden MB, Thomas R, Raskind MA. Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: a placebo-controlled study. Alzheimer Dis Assoc Disord. 2005;19(1):23–28.
   PubMed Web of Science ®Google Scholar
• Shankle WR, Nielson KA, Cotman CW. Low-dose propranolol reduces aggression and agitation resembling that associated with orbitofrontal dysfunction in elderly demented patients. Alzheimer Dis Assoc Disord. 1995;9(4):233–37.
   PubMed Web of Science ®Google Scholar
• Ratey JJ, Sorgi P, O’Driscoll GA, Sands S, Daehler ML, Fletcher JR, Kadish W, Spruiell G, Polakoff S, Lindem KJ. Nadolol to treat aggression and psychiatric symptomatology in chronic psychiatric inpatients: a double-blind, placebo-controlled study. J Clin Psychiatry. 1992;53(2):41–46.
   PubMed Web of Science ®Google Scholar
• Sorgi PJ, Ratey JJ, Polakoff S. Beta-adrenergic blockers for the control of aggressive behaviors in patients with chronic schizophrenia. Am J Psychiatry. 1986;143(6):775–76.
   PubMed Web of Science ®Google Scholar
• Ripley TL, Saseen JJ. β-blockers: a review of their pharmacological and physiological diversity in hypertension. Annuals Pharmacother. 2014;48(6):723–33.
   PubMed Web of Science ®Google Scholar